Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ERNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.30M
- EPS (TTM)
- -$11.22
- Dividend yield
- None
- 52-week range
- 1.35 – 37.50
- Day range
- 1.35 – 1.60
- Volume / Avg
- 20.38K / 43.90K
- Beta
- —
- Shares outstanding
- 1.69M
52-week range
ERNA stock today
Shares of Ernexa Therapeutics (ERNA) finished lower on Nov 20 at $1.36, a drop of 16.56% or $0.27 per share, versus the S&P 500's 3.70% decline. Trading was light, with 20.38K shares changing hands, about 46% of the average daily volume. At this level, ERNA sits near the bottom of its 52-week range of $1.35 to $37.50: 96.4% below the high and 0.7% above the low.
Ernexa Therapeutics has posted a net loss over the last twelve months (EPS of -$11.22), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ernexa Therapeutics
Company profileErnexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Sanjeev Luther
- Headquarters
- Cambridge, MA
- Employees
- 5
- Website
- ernexatx.com
Financial highlights
Full financialsErnexa Therapeutics reported a net loss of $14.1 million, compared with a loss of $44.5 million a year earlier. Diluted earnings per share came in at -$2.24.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $582.00K | $68.00K | $0 | — |
| Growth | — | +755.88% | — | — | — |
| Net income | $-14.08M | $-44.54M | $-21.67M | $-24.58M | $-122.55M |
| EPS (diluted) | $-2.24 | $-48.96 | $-4.08 | $-8.06 | $-56.61 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$30.00+2105.88%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $-1.89 vs $-3.84
- Surprise
- +50.78%
ERNA news
All ERNA news- Ernexa Therapeutics Inc. Approves $5,000 Monthly Cash Compensation for CFO Mark J. KeeleyNasdaq
- Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” SegmentGlobeNewswire
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell SeriesGlobeNewswire
Ernexa Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HCWBHCW Biologics Inc. | 0.7491 | +1.90% | $2.35M | vs ERNA |
| ONCOOnconetix Inc. | 2.89 | -8.54% | $2.37M | vs ERNA |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.2449 | +15.03% | $2.19M | vs ERNA |
| GRIGRI Bio Inc. | 1.12 | 0.00% | $2.45M | vs ERNA |
| RDHLRedhill Biopharma Ltd. ADR | 0.281 | -13.08% | $2.50M | vs ERNA |
| SXTP60 Degrees Pharmaceuticals Inc. | 0.4682 | -6.36% | $2.10M | vs ERNA |
| DRMADermata Therapeutics Inc. | 0.5095 | -4.23% | $2.51M | vs ERNA |
| KAPAKairos Pharma Ltd. | 0.4359 | -4.62% | $2.04M | vs ERNA |
Indexes, lists and sector
Ernexa Therapeutics stock FAQ
What is Ernexa Therapeutics's stock price today?
ERNA last traded at $1.36 as of Nov 20, 4:00 PM EST, down 16.56% on the day. Prices are delayed at least 15 minutes.
Who is Ernexa Therapeutics's CEO?
Mr. Sanjeev Luther is the chief executive officer of Ernexa Therapeutics Inc., which has about 5 employees.
What is the ERNA 52-week high?
The 52-week high for ERNA is $37.50 and the 52-week low is $1.35. The stock is currently 96.4% below its high.